ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events
Item 8.01 Other Events.
On April2, 2019, Adaptimmune Therapeutics plc (the “Company” or “Adaptimmune”) issued a press release announcing a presentation of initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from the first dose cohort of the Company’s ADP-A2AFP study. The data were presented during a poster session at the 2019 American Association for Cancer Research meeting in Atlanta, Georgia. The press release is furnished as Exhibit99.1 to this report and is incorporated by reference herein.
The information in Item 8.01 of this Form8-K, including the attached Exhibit99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.
Item 8.01 Financial Statements and Exhibits.
(d) Exhibits.
|
ExhibitNo. |
DescriptionofExhibit |
|
99.1 |
Press release dated April2, 2019. |
Adaptimmune Therapeutics PLC Exhibit
EX-99.1 2 a19-7472_1ex99d1.htm EX-99.1 Exhibit 99.1 Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting PHILADELPHIA,…
To view the full exhibit click here
About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.
